Down 20% over the year, is GSK’s share price a stunning bargain after its Q1 results?
GSK’s (LSE: GSK) share price is down 20% from its 15 May 12-month traded high of £18.19.
This sort of a drop could indicate that a bargain-basement buying opportunity is to be had. Or it could flag that the firm is fundamentally worth less than it was before.
I took a deep dive into the business and ran the key numbers to find out which is the case here.
One risk that could dent GSK’s future profits is further legal action connected to its Zantac drug or any others. Another is any sustained negative effect from 2 April’s US tariffs announcement.
However, the FTSE 100 giant’s 30 April Q1 2025 results saw turnover rise 4% year on year to £7.516bn. This was ahead of consensus…
